Advanced castrate resistant prostate cancer

Indication for Mitoxantrone

Population group: Suitable for men, only adults (18 years old or older)

Mitoxantrone is indicated in combination with corticosteroids for palliation (e.g. pain relief) related to advanced castrate resistant prostate cancer.

For this indication, competent medicine agencies globally authorize below treatments:

12-14 mg/m² once every 3 weeks

Route of admnistration


Defined daily dose

12 - 14 mg per m² of body surface area (BSA)

Dosage regimen

From 12 To 14 mg per m² of body surface area (BSA) once every 21 day(s)

Detailed description

Based on data from two comparative trials of mitoxantrone plus corticosteroids versus corticosteroids alone, the recommended dosage of mitoxantrone is 12 to 14 mg/m² given as a short intravenous infusion every 21 days, in combination with low oral doses of corticosteroids.

Cancer patients who received cumulative doses of 140 mg/m² either alone or in combination with other chemotherapeutic agents had a cumulative 2.6% probability of clinical congestive heart failure. For this reason, patients should be monitored for evidence of cardiac toxicity and questioned about symptoms of heart failure prior to the initiation of and during treatment.

Dosage considerations

Mitoxantrone concentrate should be slowly injected into a free flow lowing intravenous infusion of isotonic saline or 5% glucose solution over a period of not less than 3 to 5 minutes. The tubing should be inserted preferably into a large vein. If possible, avoid veins over joints or in extremities with compromised venous or lymphatic drainage.

Active ingredient

Mitoxantrone, a DNA-reactive agent that intercalates into deoxyribonucleic acid (DNA) through hydrogen bonding, causes crosslinks and strand breaks. Mitoxantrone also interferes with ribonucleic acid (RNA) and is a potent inhibitor of topoisomerase II, an enzyme responsible for uncoiling and repairing damaged DNA.

Read more about Mitoxantrone

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner